Systems Biology Integration and Screening of Reliable Prognostic Markers to Create Synergies in the Control of Lung Cancer Patients

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2020 Apr 23

PMID 32318583

Citations 9

Authors

Aman Chandra Kaushik

Aamir Mehmood

Dong-Qing Wei

Xiaofeng Dai

Affiliations

Soon will be listed here.

Abstract

This study aims to achieve a clearer and stronger understanding of all the mechanisms involved in the occurrence as well as in the progression of lung cancer along with discovering trustworthy prognostic markers. We combined four gene expression profiles (GSE19188, GSE19804, GSE101929, and GSE18842) from the GEO database and screened the commonly differentially expressed genes (CDEGs). We performed differentially expressed group analysis on CDEGs, alteration and mutational analysis, and expression level verification of core differential genes. Systems biology discoveries in our examination are predictable with past reports. Curiously, our examination revealed that screened biomarker adjustments, for the most part, coexist in lung cancer. After screening 952 CDEGs, we found that the up-regulation of neuromedin U (NMU) and GTSE1 in the case of lung cancer is related to poor prognosis. On the other hand, FOS CDKN1C expression is associated with poor prognosis and is responsible for the down-regulation of CDKN1C and FOS. Changes in these qualities are on free pathways to lung cancer and are not usually of combined quality variety. Even though biomarkers were related to both survival occasions in our examination, it gives us another point of view while playing out the investigation of hereditary changes and clinical highlights employing information mining. Based on our results, we found potential and prospective clinical applications in GTSE1, NMU, FOS, and CDKN1C to act as prognostic markers in case of lung cancer.

Citing Articles

Comprehensive analysis of the diagnostic and therapeutic value, immune infiltration, and drug treatment mechanisms of GTSE1 in lung adenocarcinoma.

Yan G, Li J, Gao X, Liu J, Feng G, Li Y Front Med (Lausanne). 2024; 11:1433601.

PMID: 39629227 PMC: 11611587. DOI: 10.3389/fmed.2024.1433601.

[Relationship between GTSE1 and Cell Cycle and Potential Regulatory Mechanisms  in Lung Cancer Cells].

Wang C, Xu J, Liu M, Liu J, Huang Y, Zhou L Zhongguo Fei Ai Za Zhi. 2024; 27(6):451-458.

PMID: 39026496 PMC: 11258651. DOI: 10.3779/j.issn.1009-3419.2024.106.13.

Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis.

Khilwani R, Singh S Biomedicines. 2023; 11(10).

PMID: 37893079 PMC: 10604646. DOI: 10.3390/biomedicines11102706.

Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside.

Jafari A, Babajani A, Sarrami Forooshani R, Yazdani M, Rezaei-Tavirani M Front Oncol. 2022; 12:819563.

PMID: 35280755 PMC: 8904739. DOI: 10.3389/fonc.2022.819563.

Identification of HMMR as a prognostic biomarker for patients with lung adenocarcinoma integrated bioinformatics analysis.

Li Z, Fei H, Lei S, Hao F, Yang L, Li W PeerJ. 2022; 9:e12624.

PMID: 35036134 PMC: 8710063. DOI: 10.7717/peerj.12624.

References

Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F . C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer. 2008; 99(8):1269-75. PMC: 2570515. DOI: 10.1038/sj.bjc.6604650. View

Pan J, Zhou H, Cooper L, Huang J, Zhu S, Zhao X . LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. Front Immunol. 2019; 10:6. PMC: 6362421. DOI: 10.3389/fimmu.2019.00006. View

Lu T, Tsai M, Lee J, Hsu C, Chen P, Lin C . Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev. 2010; 19(10):2590-7. DOI: 10.1158/1055-9965.EPI-10-0332. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Xu T, Ma M, Chi Z, Si L, Sheng X, Cui C . High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis. Cancer Sci. 2018; 109(6):1787-1798. PMC: 5989838. DOI: 10.1111/cas.13607. View

Shetzline S, Rallapalli R, Dowd K, Zou S, Nakata Y, Swider C . Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood. 2004; 104(6):1833-40. DOI: 10.1182/blood-2003-10-3577. View

Qiu Z, Li Y, Zeng B, Guan X, Li H . Downregulated CDKN1C/p57 drives tumorigenesis and associates with poor overall survival in breast cancer. Biochem Biophys Res Commun. 2018; 497(1):187-193. DOI: 10.1016/j.bbrc.2018.02.052. View

Wu X, Wang H, Lian Y, Chen L, Gu L, Wang J . GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis. Sci Rep. 2017; 7(1):5129. PMC: 5505986. DOI: 10.1038/s41598-017-05311-2. View

Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S . The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 2006; 66(19):9408-19. DOI: 10.1158/0008-5472.CAN-06-1349. View

10.

Ma W, Wang B, Zhang Y, Wang Z, Niu D, Chen S . Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis. Cancer Cell Int. 2019; 19:239. PMC: 6737627. DOI: 10.1186/s12935-019-0956-1. View

11.

Feng H, Gu Z, Li Q, Liu Q, Yang X, Zhang J . Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res. 2019; 12(1):35. PMC: 6477749. DOI: 10.1186/s13048-019-0508-2. View

12.

Teng M, Love M, Davis C, Djebali S, Dobin A, Graveley B . A benchmark for RNA-seq quantification pipelines. Genome Biol. 2016; 17:74. PMC: 4842274. DOI: 10.1186/s13059-016-0940-1. View

13.

Liu X, Li H, Song B, Liu X . Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep. 2010; 11(8):626-32. PMC: 2920445. DOI: 10.1038/embor.2010.90. View

14.

Falzone L, Lupo G, La Rosa G, Crimi S, Anfuso C, Salemi R . Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. Cancers (Basel). 2019; 11(5). PMC: 6562527. DOI: 10.3390/cancers11050610. View

15.

Zhang S, Wang Q, Han Q, Han H, Lu P . Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods. Biosci Rep. 2019; 39(4). PMC: 6443946. DOI: 10.1042/BSR20190083. View

16.

Sun Y, Jin S, Zhu Q, Han L, Feng J, Lu X . Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expression. Oncotarget. 2017; 8(17):28297-28311. PMC: 5438651. DOI: 10.18632/oncotarget.16044. View

17.

Shin J, Kim H, Lee K, Kim J, Park J, Won M . Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer. Exp Mol Med. 2000; 32(2):79-83. DOI: 10.1038/emm.2000.14. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

19.

Ketterer K, Kong B, Frank D, Giese N, Bauer A, Hoheisel J . Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett. 2009; 277(1):72-81. DOI: 10.1016/j.canlet.2008.11.028. View

20.

Piao J, Sun J, Yang Y, Jin T, Chen L, Lin Z . Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis. Gene. 2018; 647:306-311. DOI: 10.1016/j.gene.2018.01.003. View